{"id":562,"date":"2022-07-26T12:00:00","date_gmt":"2022-07-26T12:00:00","guid":{"rendered":"https:\/\/karmar.cfolks.pl\/aktualnosci\/karmar-wybuduje-ii-etap-oddzialu-produkcji-form-jalowych-i-laboratoriow-rd-dla-tzf-polfa-sa\/"},"modified":"2026-07-29T15:20:10","modified_gmt":"2026-07-29T15:20:10","slug":"karmar-wybuduje-ii-etap-oddzialu-produkcji-form-jalowych-i-laboratoriow-rd-dla-tzf-polfa-sa","status":"publish","type":"kbn_news","link":"https:\/\/karmar.com.pl\/en\/aktualnosci\/karmar-wybuduje-ii-etap-oddzialu-produkcji-form-jalowych-i-laboratoriow-rd-dla-tzf-polfa-sa\/","title":{"rendered":"Karmar will build a second-stage sterile mold manufacturing department and R&amp;D laboratories for TZF Polfa SA"},"content":{"rendered":"<p>Karmar SA has been selected as the general contractor for the construction and installation of a new freeze-drying unit, a Highly Potential drug manufacturing facility, and a R &amp; D laboratory along with equipment. A new, European-scale, highly specialized building will be built in Warsaw by order of the Tarhomin pharmaceutical plants Polfa SA.<\/p>\n<p><strong>On July 26, 2022, Karmar SA and TZF Polfa SA signed an agreement on the general implementation of the branch building for the production of sterile forms and research laboratories (R &amp; D) at 2 Fleming Street in Warsaw.<\/strong><\/p>\n<p>It is a great honor for us to have the opportunity to implement another important facility that will produce highly specialized drugs for cancer patients. Polfa Tarchomin has been building and strengthening its market position in the pharmaceutical sector for almost 200 years, so we are very pleased that Karmar's offer has met all the investor's expectations. Thus, we will do everything possible to ensure that the building that is important for you and for us is made with the highest quality. - Joanna Makowiecka-GATZA, Chairman of the Management Board of Karmar SA.<\/p>\n<p>The new building will have a production line dedicated to the production of advanced cancer and immunosuppressants, as well as a laboratory part where quality control will pass through products for the production of medicines, and a laboratory of the R&amp;D department. Outside of the production and laboratory area, the building provides: sanitary and social, office and technical premises.<\/p>\n<p>As TZF Polfa SA, we are delighted to have an experienced business partner like Karmar for this unusual task from all angles. Suffice it to mention that in addition to the impressive elements of the filling line, all installations, equipment and facilities will be qualified for EU GMP, EAEU, FDA and UAE, which will open up many new markets for TZF Polfa SA. But the most important thing is possible assistance to Polish cancer patients. &#8211; Robert CHABROS, Project Manager TZF Polfa SA.<\/p>\n<p>The building measures 69.5&#215; 52 m and is about 20 m high, and will have three aboveground floors:<\/p>\n<ul>\n<li>the first floor, where the production of standard and oncological drugs will be carried out. Both areas will be separated from each other by separate staff entrances;<\/li>\n<li>the second floor, where technical facilities will be located, such as ventilation, electrical distribution, transformer stations, server, heat exchange, compressor, media room, etc. as well as changing rooms for the staff of the oncological district;<\/li>\n<li>the third floor, where laboratories, offices and technical facilities will be located.<\/li>\n<\/ul>\n<p>Investor: Tarkhominsky Pharmaceutical Plant POLFA SA<\/p>\n<p>Substitute investor: Bilfinger Tebodin Poland LLC<\/p>\n<p> Investments in numbers:<\/p>\n<ul>\n<li>Number of buildings: 1<\/li>\n<li>Number of ground floors: 3<\/li>\n<li>Number of underground floors: 1<\/li>\n<li>Built-up area: 3,723. 90 m2<\/li>\n<li>Total area of the building: 11,594. 15 m2<\/li>\n<li>Built-up area: 14,861 m2<\/li>\n<li>Start date: August 2022<\/li>\n<\/ul>\n<p>Planned completion of the project: January implementation of facilities for the pharmaceutical and medical industry and specialized laboratories of the highest, VI degree of complexity of cubature facilities requires special knowledge and engineering competencies. Karmar has been implementing laboratory facilities and projects, including for the pharmaceutical industry, since 2009. To date, we can boast of 10 already implemented investments m.in in Krakow, Warsaw and Gdansk, as a radiotherapy center or pharmaceutical laboratories for Polpharma Biologics. Currently, we are implementing 4 specialized (medical) projects in Gdansk, Lublin and (industrial) in Olsztyn.<\/p>","protected":false},"excerpt":{"rendered":"<p>Karmar SA zosta\u0142 wybrany na generalnego wykonawc\u0119 budynku i instalacji nowego oddzia\u0142u liofilizacji, wytwarzania lek\u00f3w Highly Potent oraz laboratorium B+R wraz z urz\u0105dzeniami. Nowy, unikatowy w skali Europy,&hellip;<\/p>","protected":false},"author":1,"featured_media":563,"menu_order":12,"template":"","class_list":["post-562","kbn_news","type-kbn_news","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/karmar.com.pl\/en\/wp-json\/wp\/v2\/kbn_news\/562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/karmar.com.pl\/en\/wp-json\/wp\/v2\/kbn_news"}],"about":[{"href":"https:\/\/karmar.com.pl\/en\/wp-json\/wp\/v2\/types\/kbn_news"}],"author":[{"embeddable":true,"href":"https:\/\/karmar.com.pl\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/karmar.com.pl\/en\/wp-json\/wp\/v2\/media\/563"}],"wp:attachment":[{"href":"https:\/\/karmar.com.pl\/en\/wp-json\/wp\/v2\/media?parent=562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}